Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Subjects voluntarily provided informed consent and agreed to participate in thestudy.

• Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signingthe informed consent form).

• At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopicdermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior toscreening.

• At screening and baseline visits, subjects were required to have moderate-to-severeatopic dermatitis (AD) with all three of the following criteria satisfied:

• Total AD lesion area ≥ 10% of body surface area (BSA)

• Investigator's Global Assessment (IGA) score ≥ 3

• Eczema Area and Severity Index (EASI) score ≥ 16

Exclusion Criteria:

• Subjects with a documented history of hypersensitivity to Janus kinase (JAK)inhibitors.

• Subjects with current or a history of autoimmune diseases other than atopicdermatitis (AD) (e.g., systemic lupus erythematosus [SLE], inflammatory boweldisease [IBD], Felty's syndrome, scleroderma, inflammatory myopathy, otherconnective tissue diseases, overlap syndrome) or other skin conditions that mayinterfere with AD assessment (e.g., contact dermatitis, psoriasis).